also demonstrated potential in studies as a treatment for other metabolic and neurodegenerative diseases, such as Huntington??s Disease and NASH. In consideration of the grant of the license, the Company will be obligated to pay an annual maintenance fee until it begins commercial sales of any products developed pursuant to the License Agreement.